Arcus Biosciences Announces Participation at Upcoming Investor Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/21/2026

1. TGT
2. EL
3. SPY
4. WMT
5. ADI

6. ROST
7. BILL
8. MRK
9. MRNA
10. NTES

Get Alerts RCUS Hot Sheet

Price: $29.52 -2.73%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 8:40 am PT at the Terranea Resort, in Rancho Palos Verdes, CA.

Individuals may access the live audio webcast by visiting the “Events & Presentations” section of the Company’s website at https://investors.arcusbio.com/investors/investor-relations/default.aspx. A replay of the webcast will be available for 30 days following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist and an anti-PD-1 antibody, both of which are in Phase 1 trials, as well as a small molecule inhibitor of CD73 and an anti-TIGIT antibody, which are in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology, and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.